Adjuvant Treatment with Melphalan in Ovarian Carcinoma with no Residual Disease following Surgery
| Autor: | Regazzoni M, Zecchini Am, R. Koronel, G. Spatti, De Palo G |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Melphalan
Cancer Research medicine.medical_specialty Adjuvant chemotherapy medicine.medical_treatment Disease 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Ovarian carcinoma medicine Humans Postoperative Period Prospective Studies Stage (cooking) Borderline tumor Ovarian Neoplasms Postoperative Care business.industry General Medicine Prognosis medicine.disease Combined Modality Therapy Surgery Leukemia Oncology 030220 oncology & carcinogenesis Female business Omentum Adjuvant medicine.drug |
| Zdroj: | Tumori Journal. 73:157-162 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089168707300212 |
| Popis: | Forty-nine patients classified after surgery and complete non-surgical restaging as « no residual disease » were treated with adjuvant chemotherapy. Thirty-nine patients had ovarian carcinoma and 10 borderline tumors. All patients had geographic inaccessibility. Domiciliary treatment with melphalan at the dose of 10 mg/day p.o. for 5 consecutive days every 4 weeks for 12 cycles was used. Within 6 months from the end of adjuvant treatment a second restaging with peritoneoscopy and peritoneal cytology was performed. The median administered dose of melphalan was 575 mg. No patient with a borderline tumor relapsed. Nine patients with ovarian carcinoma relapsed (23 %): 4/10 at stage II-III and 5/29 (17 %) at stage I. The relapse-free survival at 96 months was 77 % for stage I patients and 73 % for all patients. The overall survival was 87 % for stage I patients and 81 % for all patients. Mild myelodepression was evident in 65 % of patients. No case of acute nonlymphocytic leukemia was observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|